Literature DB >> 6733585

Triazene metabolism. III. In vitro cytotoxicity towards M21 cells and in vivo antitumour activity of the proposed metabolites of the antitumour 1-aryl-3,3-dimethyltriazenes.

D J Kohlsmith, K Vaughan, S J Luner.   

Abstract

In vitro cytotoxicity of a series of antitumour triazenes towards the M21 melanoma cell line has been studied. Dimethyltriazenes are structural analogues of 5-(3,3-dimethyl-1-triazeno-)imidazole-4-carboxamide (Dacarbazine) and are inactive, which is consistent with the requirement for metabolic activation. Monomethyltriazenes and hydroxymethyltriazenes , the proposed metabolites of the dimethyltriazenes, are cytotoxic to the M21 cell line. A new series of 4-hydroxy-1,2,3- benzotriazines has been tested for in vitro cytotoxicity. A series of monoalkyltriazenes (Ar X N = N X NHR ) has been tested for antitumour activity against the P388 lymphoma in vivo. Only monomethyltriazenes had significant antitumour activity, which supports the hypothesis that the monomethyltriazene is the active metabolite of the antitumour dimethyltriazenes. The activity of monomethyltriazenes in vivo is correlated with the chemical stability and t1/2 measurements in pH 7.5 phosphate buffer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6733585     DOI: 10.1139/y84-063

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  2 in total

1.  Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes.

Authors:  G Sava; S Zorzet; L Perissin; T Giraldi; L Lassiani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOK.

Authors:  G Sava; S Zorzet; L Perissin; S Pacor; L Lassiani; C Nisi; A Varnavas
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.